Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Average Target Price of $23.40

Key Points

• Analysts are broadly cautious: Eighteen firms give Sarepta an average “Reduce” rating, with seven sells, five holds and six buys. Their average 12-month price target is $23.40, compared with the reported share price of $17.82.
• Quarterly results were mixed: Sarepta reported EPS of $0.13 and revenue of $381.35 million, beating MarketBeat’s estimates, but revenue fell 4.5% year over year. Other coverage said EPS missed a higher estimate and cited weaker Elevidys sales.
• Recent analyst actions were mixed: RBC raised its target to $18 while maintaining “sector perform,” whereas JPMorgan cut its target to $20 and kept a neutral rating; HC Wainwright reiterated a $5 sell target.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has received an average rating of "Reduce" from the eighteen research firms that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $23.40.

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a "sell" rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 5th. JPMorgan Chase & Co. cut their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating on the stock in a report on Wednesday, September 30th. Royal Bank Of Canada boosted their target price on shares of Sarepta Therapeutics from $17.00 to $18.00 and gave the stock a "sector perform" rating in a research report on Friday. Weiss Ratings downgraded shares of Sarepta Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, October 28th. Finally, Wall Street Zen lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, August 8th.

Sarepta Therapeutics Price Performance

SRPT opened at $17.82 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics has a 52-week low of $14.68 and a 52-week high of $24.68. The stock has a market capitalization of $1.88 billion, a PE ratio of -13.01, a price-to-earnings-growth ratio of 0.33 and a beta of 0.45. The stock's 50 day moving average price is $19.13 and its 200-day moving average price is $18.64.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.06. The firm had revenue of $381.35 million during the quarter, compared to the consensus estimate of $352.20 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The company's revenue for the quarter was down 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.13) EPS. On average, equities research analysts predict that Sarepta Therapeutics will post 3.27 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. acquired a new position in Sarepta Therapeutics in the 2nd quarter worth about $27,000. Pinnacle Wealth Planning Services Inc. raised its position in Sarepta Therapeutics by 50.6% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 598 shares during the last quarter. Nykredit A S purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter worth about $43,000. Ancora Advisors LLC acquired a new position in Sarepta Therapeutics in the second quarter worth about $45,000. Finally, Allworth Financial LP bought a new position in Sarepta Therapeutics in the 2nd quarter worth about $58,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $17 to $18, while maintaining a “sector perform” rating. Sarepta reported Q3 EPS of $0.13, above the $0.07 consensus cited by MarketBeat, and revenue of $381.35 million versus its $352.20 million estimate. MarketBeat earnings report
• Neutral Sentiment: Baird lowered its price target to $18. The target is close to the $17.82 share price cited in the report, suggesting limited upside at that level. StreetInsider report
• Negative Sentiment: Other earnings coverage said SRPT’s $0.13 EPS missed the Zacks consensus estimate of $0.37. Revenue was down 4.5% year over year, and reports said weaker Elevidys sales weighed on investor sentiment. Published earnings benchmarks differ, so the quarter’s result depends on which estimate is used. Zacks earnings coverage
• Negative Sentiment: A Sarepta-Hansa gene-therapy study has ended, raising questions for investors about the collaboration and its development prospects. The available report summary does not specify the study’s results or implications. TipRanks report

About Sarepta Therapeutics

Sarepta Therapeutics, Inc NASDAQ: SRPT is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company's primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.